CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

CRISPR Therapeutics AGNASDAQ: CRSP

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense turns negative

Q3 FY2026 income tax expense was -$74K, compared with $619K a year earlier. Trailing-twelve-month income tax expense was $2.34M.

Context

  • Income tax expense amounted to 103.5% of revenue in FY2025, up 93.3 pp from a year earlier.
  • Income tax expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -$74K or moves back toward the trailing-twelve-month quarterly average of $584.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$74K-107.7% QoQ
Last fiscal yearDec 2025
$3.63M+1.3% YoY
LTMSep 2026
$2.34M-37.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-112.0%——
1 year+1.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
3.63M USD
Year-over-year change
+1.3%
4-year CAGR
+18.1%

Income Tax Expense vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 income tax expense of $2.34M is the highest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of -37.1% is the highest of 2, against a peer median of -138.2%.
  • Income tax expense amounts to 9.3% of revenue for CRSP, versus a peer median of 0.0%.
CRSP Competitors Peer median
Income Tax Expense for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRSPCRISPR Therapeutics AGLTM Sep 2026$2.34M -37.1%—9.3%
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 ——0.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
RGNXREGENXBIO Inc.LTM Mar 2026$0 ——0.0%
EDITEditas Medicine, Inc.LTM Mar 2026$0 ——0.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026$0 ——0.0%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-$1.01M -138.2%—0.7%
Peer median (excluding CRSP) $0-138.2%—0.0%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue913.08M436K370M35M3.51M
Cost of Revenue101.18M110.25M130.25M110.25M232.96M
Gross Profit811.9M(109.81M)239.75M(75.25M)(229.45M)
Gross Margin88.9%-25186.7%64.8%-215.0%-6537.0%
Research & Development340.57M461.65M387.33M320.65M265.33M
Selling, General & Admin99.69M102.46M76.16M72.98M73.54M
Operating Expenses438.38M563.35M462.29M391.32M338.87M
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
EBITDA397.48M(626.33M)(130.89M)(343.41M)(558.49M)
EBITDA Margin43.5%-143653.2%-35.4%-981.2%-15911.3%
Operating Income373.53M(673.16M)(222.54M)(466.57M)(568.32M)
Operating Margin40.9%-154394.7%-60.1%-1333.0%-16191.4%
Interest Income00000
Interest Expense00000
Other Income / Expenses6M22.66M71.82M103.9M(9.65M)
Income Before Tax379.53M(650.5M)(150.72M)(362.67M)(577.97M)
Pre-Tax Margin41.6%-149197.2%-40.7%-1036.2%-16466.2%
Income Tax Expense1.87M(325K)2.89M3.59M3.63M
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Net Margin41.4%-149122.7%-41.5%-1046.4%-16569.8%
EPS (Basic)4.97(8.36)(1.94)(4.34)(6.47)
EPS (Diluted)4.70(8.36)(1.94)(4.34)(6.47)
Weighted Avg Shares75.95M77.75M79.22M84.36M89.93M
Weighted Avg Shares (Diluted)80.39M77.75M79.22M84.36M89.93M

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.